CHAMPIONS ONCOLOGY, INC. (CSBR) Debt Components
- 2017-10-30: Line of Credit Facility, Maximum Borrowing CapacityUSD $1.50M; Debt Instrument, Interest Rate, Stated Percentagepure (m); Notes Payable, Related Parties, CurrentUSD (m).
- 2015-01-31: Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m); Notes Payable, Related Parties, CurrentUSD $2.00M.
- 2014-12-01: Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure 12.00%; Notes Payable, Related Parties, CurrentUSD (m).
- 2014-04-30: Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m); Notes Payable, Related Parties, CurrentUSD $0.00.
CHAMPIONS ONCOLOGY, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Line of Credit Facility, Maximum Borrowing Capacity USD | Debt Instrument, Interest Rate, Stated Percentage pure | Notes Payable, Related Parties, Current USD |
|---|---|---|---|
| 2017-10-30 | $1.50M | (m) | (m) |
| 2015-01-31 | (m) | (m) | $2.00M |
| 2014-12-01 | (m) | 12.00% | (m) |
| 2014-04-30 | (m) | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |